Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease

Posted by & filed under News.

PITTSBURGH, Nov 8, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that patient treatment has begun in the Phase 2 SHINE study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. SHINE (Synaptic Health… Read more »